Skip to content

To rise above the flood of dropsiDose TR delivers as designed

In 2 pivotal trials, iDose TR achieved the prespecified primary efficacy endpoint (noninferiority to topical timolol through 3 months).1

Range of IOP Reductions through 3 Months: Phase 3 Trials 1 diagram

Noninferiority of iDose TR to timolol was established if the upper limit of the 2-sided 95% confidence interval for the difference in the mean of change from baseline in IOP was 
<1.5 mmHg at each of the 6 post-baseline timepoints and was <1 mmHg at 3 or more of the 6 post-baseline timepoints.2,3

Trial design: iDose TR was evaluated for efficacy and safety in patients with OHT and OAG. Two identically designed, Phase 3, parallel-group, double-masked, randomized, prospective, sham-controlled trials compared iDose TR with topical timolol (0.5%) BID. The primary endpoint was the change in diurnal IOP (vs timolol) through 3 months post implantation. Patients aged ≥18 years with OAG (POAG, PXG, or PG) or OHT, with a C/D ratio of ≥0.8, and with a BSCVA of 20/80 or better were included in the study. Change was assessed from a time-matched baseline in IOP from 8 AM and 10 AM at Day 10, Week 6, and 
Month 3. Mean baseline IOP was 24.6 mmHg.1-3

BSCVA=best spectacle-corrected visual acuity; C/D=cup-to-disc; OAG=open-angle glaucoma; OHT=ocular hypertension; PG=pigmentary glaucoma; POAG=primary open-angle glaucoma; PXG=pseudoexpoliative glaucoma.

Enduring control at 12 months3,*

81%

of iDose TR patients were completely free of IOP-lowering topical medications (23% were originally on 2+ medications pre trial)

ABOUT iDOSE TR

iDOSE TR SAFETY

Ready to hear more?

Contact a representative to request more info.

*iDose TR clinical results shown represent the approved and commercially marketed version, identified as the “slow-eluting implant arm” in the pivotal trials.4

References: 1. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023. 2. Sarkisian SR Jr, Ang RE, Lee AM, et al; GC-010 Travoprost Intraocular Implant Investigators. Phase 3 randomized clinical trial of the safety and efficacy of travoprost intraocular implant in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2024;131(9):1021-1032. 3. Sarkisian SR, Ang RE, Lee AM, et al. Travoprost intracameral implant for open-angle glaucoma or ocular hypertension: 12-month results of a randomized, double-masked trial. Ophthalmol Ther. 2024;13(4):995-1014. 4. Berdahl JP, Sarkisian SR Jr, Ang RE, et al. Efficacy and safety of the travoprost intraocular implant in reducing topical IOP‐lowering medication burden in patients with open‐angle glaucoma or ocular hypertension. Drugs. 2024;84(1):83-97.

Important Safety Information

Dosage and Administration

For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

Contraindications

iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings and Precautions

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Indications and Usage

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Please see full Prescribing Information.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

The information contained in this site is intended for US healthcare professionals only.

YES, I AM A US HEALTHCARE PROFESSIONAL NO, I AM NOT A US HEALTHCARE PROFESSIONAL

Request more info

"*" indicates required fields

*Required.

By entering this information, you confirm that you are at least 18 years old and that you have read and accept the terms of our Privacy Policy. Glaukos will use the information you provide on this form to provide product updates and other promotional materials. Should you change your mind, you may unsubscribe using the link in the footer of any email you receive from us.

Stay connected

Sign up to receive the latest information about iDose® TR!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
*Required.

Glaukos will use the information you provide on this form to get in touch with you.

By entering this information, you confirm that you are at least 18 years old and that you have read and accept the terms of our Privacy Policy. Glaukos will use the information you provide on this form to provide product updates and other promotional materials. Should you change your mind, you may unsubscribe using the link in the footer of any email you receive from us.